Announcement • Jun 30
Zhejiang NHU Company Ltd. to Report First Half, 2026 Results on Aug 20, 2026 Zhejiang NHU Company Ltd. announced that they will report first half, 2026 results on Aug 20, 2026 Announcement • Jun 25
Zhejiang NHU Company Ltd. (SZSE:002001) announces an Equity Buyback for CNY 600 million worth of its shares. Zhejiang NHU Company Ltd. (SZSE:002001) announces a share repurchase program. Under the program, the company will repurchase up to CNY 600 million worth of its shares. The price for the share repurchase will not exceed CNY 45.5 per share. The shares repurchased will be used for equity incentive or employee stock ownership plan and shares not used within 3 years after the completion of the repurchase will be cancelled. The program will be funded using the company's own funds. The program is valid for 12 months from board approval date. Declared Dividend • May 23
Dividend of CN¥0.80 announced Shareholders will receive a dividend of CN¥0.80. Ex-date: 28th May 2026 Payment date: 28th May 2026 Dividend yield will be 3.2%, which is higher than the industry average of 2.6%. Sustainability & Growth Dividend is well covered by both earnings (46% earnings payout ratio) and cash flows (44% cash payout ratio). The dividend has increased by an average of 28% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 36% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Apr 17
Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2025 results: EPS: CN¥2.21 (up from CN¥1.91 in FY 2024). Revenue: CN¥22.3b (up 3.0% from FY 2024). Net income: CN¥6.76b (up 15% from FY 2024). Profit margin: 30% (up from 27% in FY 2024). The increase in margin was primarily driven by higher revenue. Revenue missed analyst estimates by 4.2%. Earnings per share (EPS) exceeded analyst estimates by 1.6%. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth. Price Target Changed • Apr 16
Price target increased by 7.3% to CN¥36.00 Up from CN¥33.55, the current price target is an average from 6 analysts. New target price is approximately in line with last closing price of CN¥37.62. Stock is up 75% over the past year. Announcement • Apr 16
Zhejiang NHU Company Ltd., Annual General Meeting, May 15, 2026 Zhejiang NHU Company Ltd., Annual General Meeting, May 15, 2026, at 14:30 China Standard Time. Location: The Company's Meeting Room, Xinchang County, Zhejiang China Announcement • Mar 31
Zhejiang NHU Company Ltd. to Report Q1, 2026 Results on Apr 29, 2026 Zhejiang NHU Company Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026 Price Target Changed • Mar 21
Price target increased by 14% to CN¥33.55 Up from CN¥29.38, the current price target is an average from 6 analysts. New target price is approximately in line with last closing price of CN¥34.25. Stock is up 59% over the past year. The company is forecast to post earnings per share of CN¥2.18 for next year compared to CN¥1.91 last year. Price Target Changed • Mar 11
Price target increased by 14% to CN¥33.55 Up from CN¥29.38, the current price target is an average from 6 analysts. New target price is 13% below last closing price of CN¥38.67. Stock is up 76% over the past year. The company is forecast to post earnings per share of CN¥2.18 for next year compared to CN¥1.91 last year. Valuation Update With 7 Day Price Move • Mar 06
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CN¥36.30, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 26x in the Chemicals industry in China. Total returns to shareholders of 117% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥57.58 per share. Announcement • Dec 31
Zhejiang NHU Company Ltd. to Report Fiscal Year 2025 Results on Apr 16, 2026 Zhejiang NHU Company Ltd. announced that they will report fiscal year 2025 results on Apr 16, 2026 Reported Earnings • Oct 29
Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2025 results: EPS: CN¥0.56 (down from CN¥0.58 in 3Q 2024). Revenue: CN¥5.54b (down 6.7% from 3Q 2024). Net income: CN¥1.72b (down 3.8% from 3Q 2024). Profit margin: 31% (in line with 3Q 2024). Revenue missed analyst estimates by 9.0%. Earnings per share (EPS) exceeded analyst estimates by 13%. Revenue is forecast to grow 9.2% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Oct 13
Upcoming dividend of CN¥0.20 per share Eligible shareholders must have bought the stock before 20 October 2025. Payment date: 20 October 2025. Payout ratio is a comfortable 21% and this is well supported by cash flows. Trailing yield: 2.1%. Within top quartile of Chinese dividend payers (1.9%). Higher than average of industry peers (1.4%). Announcement • Sep 30
Zhejiang NHU Company Ltd. to Report Q3, 2025 Results on Oct 29, 2025 Zhejiang NHU Company Ltd. announced that they will report Q3, 2025 results on Oct 29, 2025 Announcement • Sep 16
Zhejiang Nhu Company Ltd. Approves Interim Dividend for 2025 Zhejiang NHU Company Ltd. held its 2nd Extraordinary General Meeting of 2025 on 12 September 2025, approved interim Cash dividend/10 shares (tax included): CNY2.00000000 for 2025. Announcement • Aug 29
Zhejiang Nhu Company Ltd. Proposes Interim Cash Dividend for 2025 Zhejiang NHU Company Ltd. proposed 2025 interim dividend at its EGM to be held on 12 September 2025, a Cash dividend (tax included) of CNY 2.00000000 per ten shares. Reported Earnings • Aug 28
Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2025 results: EPS: CN¥0.56 (up from CN¥0.43 in 2Q 2024). Revenue: CN¥5.66b (up 5.9% from 2Q 2024). Net income: CN¥1.72b (up 29% from 2Q 2024). Profit margin: 30% (up from 25% in 2Q 2024). The increase in margin was primarily driven by higher revenue. Revenue missed analyst estimates by 2.0%. Earnings per share (EPS) exceeded analyst estimates by 13%. Revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Announcement • Jul 02
Zhejiang NHU Company Ltd. to Report First Half, 2025 Results on Aug 28, 2025 Zhejiang NHU Company Ltd. announced that they will report first half, 2025 results on Aug 28, 2025 Declared Dividend • May 19
Dividend of CN¥0.50 announced Shareholders will receive a dividend of CN¥0.50. Ex-date: 21st May 2025 Payment date: 21st May 2025 Dividend yield will be 3.1%, which is higher than the industry average of 2.6%. Sustainability & Growth Dividend is well covered by both earnings (22% earnings payout ratio) and cash flows (22% cash payout ratio). The dividend has increased by an average of 13% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 9.3% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Apr 15
Full year 2024 earnings: EPS and revenues exceed analyst expectations Full year 2024 results: EPS: CN¥1.91 (up from CN¥0.88 in FY 2023). Revenue: CN¥21.6b (up 43% from FY 2023). Net income: CN¥5.87b (up 117% from FY 2023). Profit margin: 27% (up from 18% in FY 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) also surpassed analyst estimates by 4.2%. Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Announcement • Apr 15
Zhejiang NHU Company Ltd., Annual General Meeting, May 08, 2025 Zhejiang NHU Company Ltd., Annual General Meeting, May 08, 2025, at 14:30 China Standard Time. Location: The Company's Meeting Room, Xinchang County, Zhejiang China Announcement • Mar 31
Zhejiang NHU Company Ltd. to Report Q1, 2025 Results on Apr 29, 2025 Zhejiang NHU Company Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025 Major Estimate Revision • Jan 28
Consensus EPS estimates increase by 14% The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate increased from CN¥1.70 to CN¥1.94. Revenue forecast steady at CN¥21.3b. Net income forecast to grow 26% next year vs 51% growth forecast for Chemicals industry in China. Consensus price target of CN¥26.07 unchanged from last update. Share price rose 2.0% to CN¥22.51 over the past week. Major Estimate Revision • Jan 24
Consensus EPS estimates increase by 19% The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate increased from CN¥1.62 to CN¥1.93. Revenue forecast steady at CN¥21.3b. Net income forecast to grow 23% next year vs 51% growth forecast for Chemicals industry in China. Consensus price target of CN¥26.07 unchanged from last update. Share price rose 2.7% to CN¥22.49 over the past week. Announcement • Jan 16
Zhejiang Nhu Company Ltd. Announces Special Dividend of the Year 2024 of A Shares, Payable on 22 January 2025 Zhejiang NHU Company Ltd. announced special cash dividend/10 shares (tax included) of CNY 5.00000000 for year 2024 of A shares. Record date is 21 January 2025. Ex-date is 22 January 2025. Payment date is 22 January 2025. Announcement • Dec 31
Zhejiang NHU Company Ltd. to Report Fiscal Year 2024 Results on Apr 15, 2025 Zhejiang NHU Company Ltd. announced that they will report fiscal year 2024 results on Apr 15, 2025 Announcement • Dec 20
Zhejiang NHU Company Ltd. Proposes Special Cash Dividend for the Third Quarter of 2024 Zhejiang NHU Company Ltd. proposed special cash dividend of CNY 2.00 per 10 shares for the third quarter of 2024. Major Estimate Revision • Oct 30
Consensus EPS estimates increase by 25% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from CN¥19.6b to CN¥21.1b. EPS estimate increased from CN¥1.49 to CN¥1.86 per share. Net income forecast to grow 17% next year vs 51% growth forecast for Chemicals industry in China. Consensus price target up from CN¥23.51 to CN¥25.41. Share price fell 6.1% to CN¥22.92 over the past week. Price Target Changed • Oct 26
Price target increased by 8.1% to CN¥25.41 Up from CN¥23.51, the current price target is an average from 7 analysts. New target price is 11% above last closing price of CN¥22.93. Stock is up 44% over the past year. The company is forecast to post earnings per share of CN¥1.86 for next year compared to CN¥0.87 last year. Price Target Changed • Oct 24
Price target increased by 11% to CN¥25.11 Up from CN¥22.58, the current price target is an average from 7 analysts. New target price is 6.1% above last closing price of CN¥23.67. Stock is up 53% over the past year. The company is forecast to post earnings per share of CN¥1.86 for next year compared to CN¥0.87 last year. Reported Earnings • Oct 24
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Third quarter 2024 results: EPS: CN¥0.58 (up from CN¥0.20 in 3Q 2023). Revenue: CN¥5.94b (up 65% from 3Q 2023). Net income: CN¥1.79b (up 189% from 3Q 2023). Profit margin: 30% (up from 17% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 20%. Earnings per share (EPS) also surpassed analyst estimates by 35%. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Announcement • Sep 30
Zhejiang NHU Company Ltd. to Report Q3, 2024 Results on Oct 24, 2024 Zhejiang NHU Company Ltd. announced that they will report Q3, 2024 results on Oct 24, 2024 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CN¥22.57, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 16x in the Chemicals industry in China. Total returns to shareholders of 9.6% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥43.46 per share. Reported Earnings • Aug 23
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Second quarter 2024 results: EPS: CN¥0.43 (up from CN¥0.27 in 2Q 2023). Revenue: CN¥5.35b (up 41% from 2Q 2023). Net income: CN¥1.33b (up 59% from 2Q 2023). Profit margin: 25% (up from 22% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 15%. Earnings per share (EPS) also surpassed analyst estimates by 32%. Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Announcement • Jun 29
Zhejiang NHU Company Ltd. to Report First Half, 2024 Results on Aug 23, 2024 Zhejiang NHU Company Ltd. announced that they will report first half, 2024 results on Aug 23, 2024 Price Target Changed • May 30
Price target increased by 7.9% to CN¥20.82 Up from CN¥19.29, the current price target is an average from 7 analysts. New target price is 10% above last closing price of CN¥18.88. Stock is up 24% over the past year. The company is forecast to post earnings per share of CN¥1.26 for next year compared to CN¥0.87 last year. Announcement • May 25
Zhejiang NHU Company Ltd. Proposes Final Cash Dividend (A Shares) for the Year 2023, Payable on 29 May 2024 Zhejiang NHU Company Ltd. Proposed final cash dividend (A shares) (tax included) of CNY 4.50000000 per ten shares for the year 2023. Record date: 28 May 2024, Ex-date: 29 May 2024, Payment date: 29 May 2024. Net cash dividend/10 shares after tax: CNY 4.05000000 (CNY 4.50000000- CNY 0.45000000). Reported Earnings • Apr 24
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥0.88 (down from CN¥1.17 in FY 2022). Revenue: CN¥15.1b (down 5.1% from FY 2022). Net income: CN¥2.70b (down 25% from FY 2022). Profit margin: 18% (down from 23% in FY 2022). Revenue missed analyst estimates by 2.1%. Earnings per share (EPS) also missed analyst estimates by 6.4%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 12% per year whereas the company’s share price has fallen by 13% per year. Announcement • Apr 23
Zhejiang NHU Company Ltd., Annual General Meeting, May 15, 2024 Zhejiang NHU Company Ltd., Annual General Meeting, May 15, 2024, at 14:30 China Standard Time. Location: The Company's Meeting Room, Xinchang County, Zhejiang China Announcement • Mar 30
Zhejiang NHU Company Ltd. to Report Q1, 2024 Results on Apr 30, 2024 Zhejiang NHU Company Ltd. announced that they will report Q1, 2024 results on Apr 30, 2024 Announcement • Dec 29
Zhejiang NHU Company Ltd. to Report Fiscal Year 2023 Results on Apr 23, 2024 Zhejiang NHU Company Ltd. announced that they will report fiscal year 2023 results on Apr 23, 2024 Major Estimate Revision • Nov 02
Consensus EPS estimates fall by 12% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from CN¥16.6b to CN¥16.3b. EPS estimate also fell from CN¥1.09 per share to CN¥0.952 per share. Net income forecast to grow 43% next year vs 29% growth forecast for Pharmaceuticals industry in China. Consensus price target broadly unchanged at CN¥20.23. Share price rose 4.2% to CN¥16.16 over the past week. Reported Earnings • Oct 27
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Third quarter 2023 results: EPS: CN¥0.20 (down from CN¥0.26 in 3Q 2022). Revenue: CN¥3.59b (down 2.7% from 3Q 2022). Net income: CN¥618.0m (down 23% from 3Q 2022). Profit margin: 17% (down from 22% in 3Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates by 25%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 8% per year. Announcement • Sep 30
Zhejiang NHU Company Ltd. to Report Q3, 2023 Results on Oct 27, 2023 Zhejiang NHU Company Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023 Announcement • Sep 21
Zhejiang NHU Company Ltd. Announces Executive Appointments Zhejiang NHU Company Ltd. at the Extraordinary General Meeting of 2023 on 19 September 2023 approved election of non-independent directors, cumulative voting system applicable: Yu Hongwei; Election of independent directors, cumulative voting system applicable: Shen Yuping, Wan Feng, Wang Yang; Election of non-employee supervisors, cumulative voting system applicable: Zhao Jia and Wang Xiaobi. Major Estimate Revision • Sep 05
Consensus EPS estimates fall by 13% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from CN¥17.4b to CN¥16.7b. EPS estimate also fell from CN¥1.25 per share to CN¥1.08 per share. Net income forecast to grow 34% next year vs 28% growth forecast for Pharmaceuticals industry in China. Consensus price target down from CN¥21.20 to CN¥20.63. Share price rose 2.1% to CN¥16.33 over the past week. Reported Earnings • Aug 30
Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2023 results: EPS: CN¥0.27 (down from CN¥0.33 in 2Q 2022). Revenue: CN¥3.81b (down 2.6% from 2Q 2022). Net income: CN¥840.1m (down 17% from 2Q 2022). Profit margin: 22% (down from 26% in 2Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue missed analyst estimates by 11%. Earnings per share (EPS) exceeded analyst estimates by 9.3%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 13% per year, which means it is performing significantly worse than earnings. Announcement • Jun 09
Zhejiang NHU Company Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on June 14, 2023 Zhejiang NHU Company Ltd. announced final cash dividend/10 shares (tax included) of CNY 5.00000000 on A shares for the year 2022. Record date is June 13, 2023. Ex-date is May June 14, 2023. Payment date is June 14, 2023. Announcement • May 23
Zhejiang NHU Company Ltd. Approves Cash Dividend for 2022 Zhejiang NHU Company Ltd. at its Annual General Meeting of 2022 held on 19 May 2023, approved cash dividend/10 shares (tax included): CNY 5.00000000. Price Target Changed • Apr 29
Price target decreased by 13% to CN¥21.23 Down from CN¥24.35, the current price target is an average from 7 analysts. New target price is 24% above last closing price of CN¥17.07. Stock is down 23% over the past year. The company is forecast to post earnings per share of CN¥1.19 for next year compared to CN¥1.17 last year. Major Estimate Revision • Apr 27
Consensus EPS estimates fall by 11%, revenue upgraded The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from CN¥17.6b to CN¥18.1b. EPS estimate fell from CN¥1.41 to CN¥1.25 per share. Net income forecast to grow 38% next year vs 28% growth forecast for Pharmaceuticals industry in China. Consensus price target down from CN¥24.35 to CN¥23.41. Share price fell 2.8% to CN¥17.17 over the past week. Reported Earnings • Apr 21
First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2023 results: EPS: CN¥0.21 (down from CN¥0.39 in 1Q 2022). Revenue: CN¥3.61b (down 16% from 1Q 2022). Net income: CN¥643.2m (down 47% from 1Q 2022). Profit margin: 18% (down from 28% in 1Q 2022). The decrease in margin was driven by lower revenue. Revenue exceeded analyst estimates by 15%. Earnings per share (EPS) missed analyst estimates by 28%. Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 25
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2022 results: EPS: CN¥1.18 (down from CN¥1.40 in FY 2021). Revenue: CN¥15.9b (up 7.7% from FY 2021). Net income: CN¥3.64b (down 16% from FY 2021). Profit margin: 23% (down from 29% in FY 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) missed analyst estimates by 12%. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Price Target Changed • Dec 05
Price target decreased to CN¥24.38 Down from CN¥26.56, the current price target is an average from 7 analysts. New target price is 21% above last closing price of CN¥20.09. Stock is down 14% over the past year. The company is forecast to post earnings per share of CN¥1.34 for next year compared to CN¥1.40 last year. Major Estimate Revision • Nov 01
Consensus EPS estimates fall by 15% The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from CN¥15.9b to CN¥15.4b. EPS estimate also fell from CN¥1.52 per share to CN¥1.30 per share. Net income forecast to grow 24% next year vs 38% growth forecast for Pharmaceuticals industry in China. Consensus price target down from CN¥28.64 to CN¥26.56. Share price was steady at CN¥17.92 over the past week. Price Target Changed • Oct 27
Price target decreased to CN¥26.56 Down from CN¥28.64, the current price target is an average from 6 analysts. New target price is 44% above last closing price of CN¥18.38. Stock is down 19% over the past year. The company is forecast to post earnings per share of CN¥1.30 for next year compared to CN¥1.40 last year. Reported Earnings • Oct 27
Third quarter 2022 earnings: EPS misses analyst expectations Third quarter 2022 results: EPS: CN¥0.26 (down from CN¥0.31 in 3Q 2021). Revenue: CN¥3.69b (up 13% from 3Q 2021). Net income: CN¥797.2m (down 17% from 3Q 2021). Profit margin: 22% (down from 30% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 32%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Oct 24
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥18.31, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total returns to shareholders of 40% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥16.65 per share. Reported Earnings • Aug 24
Second quarter 2022 earnings: EPS and revenues exceed analyst expectations Second quarter 2022 results: EPS: CN¥0.33 (down from CN¥0.41 in 2Q 2021). Revenue: CN¥3.91b (up 11% from 2Q 2021). Net income: CN¥1.01b (down 21% from 2Q 2021). Profit margin: 26% (down from 36% in 2Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) also surpassed analyst estimates by 2.4%. Over the next year, revenue is forecast to grow 9.6%, compared to a 23% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Announcement • May 19
Zhejiang NHU Company Ltd. Announces Implementation of Final Cash Dividend for 2021, Payable on 25 May 2022 Zhejiang NHU Company Ltd. announced implementation of final cash dividend of CNY 7.00000000 per 10 A shares (tax included) for 2021. Record date is 24 May 2022 with Ex-date on 25 May 2022 and Payment date on 25 May 2022. 10% withholding tax on cash dividend will be deducted in CNY within the cash dividend receivable. Net cash dividend/10 shares after tax: CNY 6.30000000 (CNY 7.00000000 - CNY 0.70000000). Announcement • May 13
Zhejiang Nhu Company Approves Cash Dividend for 2021 Zhejiang NHU Company Ltd. approved final cash dividend of CNY 7.00000000 per 10 shares (tax included) for 2021 at its Annual General Meeting held on May 10, 2022. Reported Earnings • Apr 28
First quarter 2022 earnings: EPS and revenues exceed analyst expectations First quarter 2022 results: EPS: CN¥0.47 (up from CN¥0.44 in 1Q 2021). Revenue: CN¥4.31b (up 15% from 1Q 2021). Net income: CN¥1.20b (up 5.9% from 1Q 2021). Profit margin: 28% (down from 30% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 50%. Earnings per share (EPS) also surpassed analyst estimates by 37%. Over the next year, revenue is forecast to grow 7.4%, compared to a 26% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth. Reported Earnings • Apr 16
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2021 results: EPS: CN¥1.68 (up from CN¥1.38 in FY 2020). Revenue: CN¥14.8b (up 44% from FY 2020). Net income: CN¥4.32b (up 21% from FY 2020). Profit margin: 29% (down from 35% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) missed analyst estimates by 2.2%. Over the next year, revenue is forecast to grow 7.6%, compared to a 28% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year and the company’s share price has also increased by 22% per year. Reported Earnings • Mar 02
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: EPS: CN¥1.67 (up from CN¥1.38 in FY 2020). Revenue: CN¥14.8b (up 43% from FY 2020). Net income: CN¥4.31b (up 21% from FY 2020). Profit margin: 29% (down from 35% in FY 2020). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 4.4%. Earnings per share (EPS) also missed analyst estimates by 11%. Over the next year, revenue is forecast to grow 5.1%, compared to a 25% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth. Price Target Changed • Nov 23
Price target decreased to CN¥35.24 Down from CN¥38.01, the current price target is an average from 12 analysts. New target price is 23% above last closing price of CN¥28.73. Stock is up 4.2% over the past year. The company is forecast to post earnings per share of CN¥1.74 for next year compared to CN¥1.38 last year. Reported Earnings • Nov 01
Third quarter 2021 earnings released: EPS CN¥0.38 (vs CN¥0.28 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: CN¥3.26b (up 50% from 3Q 2020). Net income: CN¥957.6m (up 32% from 3Q 2020). Profit margin: 29% (down from 34% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Aug 21
Zhejiang NHU Company Ltd. (SZSE:002001) announces an Equity Buyback for CNY 600 million worth of its shares. Zhejiang NHU Company Ltd. (SZSE:002001) announces a share repurchase program. Under the program, the company will repurchase up to CNY 600 million worth of its shares. The shares will be repurchased at a price not more than CNY 41 per share. The repurchases will be funded using company's own funds. The shares repurchased will be used for equity incentive plan or or employee stock ownership plans. The program will be valid for 12 months. Reported Earnings • Aug 20
Second quarter 2021 earnings released: EPS CN¥0.49 (vs CN¥0.51 in 2Q 2020) The company reported a mediocre second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥3.51b (up 31% from 2Q 2020). Net income: CN¥1.27b (down 2.8% from 2Q 2020). Profit margin: 36% (down from 49% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth. Announcement • May 13
Zhejiang Nhu Company Ltd. Announces Final Cash Dividend on its A share for 2020, Payable on 19 May 2021 Zhejiang NHU Company Ltd. announces cash dividend/10 shares (tax included) of CNY 7.00000000 on its A share as 2020 final profit distribution. Payment date is 19 May 2021, record date is 18 May 2021 and ex date is 19 May 2021. Price Target Changed • May 01
Price target increased to CN¥45.39 Up from CN¥42.16, the current price target is an average from 12 analysts. New target price is 16% above last closing price of CN¥39.11. Stock is up 43% over the past year. Reported Earnings • Apr 29
First quarter 2021 earnings released: EPS CN¥0.53 (vs CN¥0.42 in 1Q 2020) The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2021 results: Revenue: CN¥3.74b (up 43% from 1Q 2020). Net income: CN¥1.14b (up 26% from 1Q 2020). Profit margin: 30% (down from 34% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Apr 01
Full year 2020 earnings released: EPS CN¥1.66 (vs CN¥1.01 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥10.3b (up 35% from FY 2019). Net income: CN¥3.56b (up 64% from FY 2019). Profit margin: 35% (up from 28% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Feb 25
Zhejiang NHU Company Ltd. to Report Fiscal Year 2020 Results on Mar 31, 2021 Zhejiang NHU Company Ltd. announced that they will report fiscal year 2020 results on Mar 31, 2021 Is New 90 Day High Low • Feb 18
New 90-day high: CN¥42.75 The company is up 28% from its price of CN¥33.31 on 20 November 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥19.02 per share. Is New 90 Day High Low • Jan 20
New 90-day high: CN¥41.05 The company is up 43% from its price of CN¥28.62 on 22 October 2020. The Chinese market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥19.55 per share. Valuation Update With 7 Day Price Move • Jan 07
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥39.29, the stock is trading at a trailing P/E ratio of 24.7x, up from the previous P/E ratio of 21.2x. This compares to an average P/E of 33x in the Pharmaceuticals industry in China. Total returns to shareholders over the past three years are 80%. Valuation Update With 7 Day Price Move • Jan 05
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥37.77, the stock is trading at a trailing P/E ratio of 23.8x, up from the previous P/E ratio of 20.6x. This compares to an average P/E of 33x in the Pharmaceuticals industry in China. Total returns to shareholders over the past three years are 70%. Is New 90 Day High Low • Dec 31
New 90-day high: CN¥33.68 The company is up 13% from its price of CN¥29.79 on 30 September 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥18.31 per share. Is New 90 Day High Low • Dec 09
New 90-day high: CN¥33.40 The company is up 8.0% from its price of CN¥30.86 on 10 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥15.70 per share. Reported Earnings • Oct 29
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥3.40b, up 51% from the prior year. Total revenue was CN¥9.33b over the last 12 months, up 21% from the prior year. Analyst Estimate Surprise Post Earnings • Oct 29
Third-quarter earnings released: Revenue and earnings miss expectations Third-quarter revenue missed analyst estimates by 31% at CN¥2.18b. Earnings per share (EPS) also missed analyst estimates by 37% at CN¥0.34. Revenue is forecast to grow 45% over the next year, compared to a 30% growth forecast for the Pharmaceuticals industry in China. Is New 90 Day High Low • Oct 19
New 90-day low: CN¥28.51 The company is down 7.0% from its price of CN¥30.50 on 21 July 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥16.34 per share. Announcement • Sep 17
Zhejiang NHU Company Ltd. Announces Management Changes Zhejiang NHU Company Ltd. in its Extraordinary General Meeting of 2020 held on 15 September 2020, approved election of Hu Baifan, Hu Baishan, Shi Guanqun, Wang Xuewen, Wang Zhengjiang, Zhou Guiyang and Yu Baijin as non-independent directors, election of Huang Can, Jin Zanfang, Zhu Jianmin and Ji Jianyang as independent directors and election of Lv Guofeng, Shi Fangbin and Yu Hongwei as non-employee supervisors, cumulative voting system applicable.